December 2012
New Oral Androgen Receptor Pathway Agents Are Changing the Way Prostate Cancer Is Treated
January 18th 2013The treatment of late-stage prostate cancer is shifting; with the approval of two new oral agents there are now more options for men with metastatic prostate cancer then just two years ago.
A United Front: Chesapeake Urology Associates Puts Its Singular Spin on Integrative Care
January 17th 2013When the founding partners of Chesapeake Urology Associates (CUA) in Maryland decided to merge their practices, Sanford J. Siegel, MD, CUA's president and CEO, drew inspiration from another consolidation process.
Multidisciplinary Prostate Cancer Care at Duke Cancer Institute: An Interview With Judd W. Moul, MD
January 16th 2013Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
